LSI is Officially Heading to Singapore — Register for LSI Asia '25 Today
Learn More About TRACON Pharmaceuticals (aka TRACON PHARMA)
TRACON Pharmaceuticals (aka TRACON PHARMA)
image
1-TRC105 is a Phase 2 monoclonal antibody that binds CD105 (endoglin), a membrane receptor on endothelial cells that is required for angiogenesis; it is expected to complement chemotherapy and treatment with VEGF inhibitors, including Avastin(R) or Lucentis(R). 2-TRC102 is a Phase 2 ready small molecule inhibitor of base excision repair that reverses resistance to antimetabolite and alkylating agent chemotherapies
Technology/product details
Revenue projections
Capital raised to date
Growth strategy
Competing Startups
More

Get a Demo and See the Full Profile

Get a demo today to see profiles of Spineology plus 6164 other startups.

Trusted By The Companies Pioneering What’s Next